A complex, chronic, and debilitating condition, inflammatory bowel disease (IBD) affects roughly 3 million Americans, including those with Crohn's disease and ulcerative colitis.

The drug has received a nod from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP).

Insights, Trends, Opportunities, and Recent DevelopmentsNew York, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Market Overview The global gastroenterology market is projected to reach USD 38.5 billion by 2024 ...

The CHMP's opinion is based on late-stage data, which show that LLY's Omvoh is effective in Crohn's disease patients with or ...

The disease is more common than you may realize; a study led by the Crohn's & Colitis Foundation found nearly 1 in 100 people living in the U.S. have IBD. The two most common forms of IBD are Crohn's ...

ORLANDO -- A considerable amount of variability exists in surgical management of ileosigmoid fistulas in Crohn's disease (CD) ...

Gavin Anumene, a fan of anime, Lego and video games — as is right and proper at age 8 — has already logged more time in a ...

The Helmsley Charitable Trust issued a $3,035,566 grant to three researchers to explore the effects of GLP-1s, including Ozempic and Wegovy, on patients with Crohn’s disease. The effort will be led by ...

Inflammatory bowel disease (IBD) is a chronic inflammation of the digestive tract. It includes conditions such as ulcerative colitis and Crohn’s disease. People with IBD may experience persistent symp ...

Thankfully, the drug price reforms in the Inflation Reduction Act respond to the needs of millions of patients like myself ...

(RTTNews) - Eli Lilly and Company (LLY) Friday said that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Omvoh for the treatment ...

Merck & Co.’s kidney cancer drug Welireg, Bayer and BridgeBio’s transthyretin amyloid cardiomyopathy (ATTR-CM) therapy, and ...